CONTINUE TO SITE
OR WAIT 15 SECS
FibroGen, Inc. has announced the sale of its China subsidiary to AstraZeneca for approximately $160 million. U
Singapore-based biopharmaceutical company Specialised Therapeutics (ST) has received the registration of
The Hunter Medical Research Institute (HMRI) has announced a new partnership with Novartis Australia, formalis
Infinitus (China) Company has secured approval for its Sino-British Joint Laboratory on Health and Ageing proj
In a breakthrough for the advanced study of gut health, scientists at the National University of Singapore (NU
The Ministry of Science and ICT and the Korea Research Institute of Bioscience and Biotechnology have announce
ZEISS Medical Technology has announced that the National Medical Products Administration (NMPA) in China&
Olympus Corporation of Asia Pacific (APAC) has announced a milestone for its iTind device with expanded availa
China-based WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Or
Novotech, a global full-service clinical Contract Research Organisation (CRO) that partners with biotech and s
Mitigating PATENT CLIFF Fallout
Monoclonal antibodies (mAbs) represent a $279.8 billion market, projected to reach $804 billion by 2033, according to a report from Dimension Market Research. With patents for many of these valuable drugs set to expire in the coming years, the industry faces significant challenges. In this story, we examine 11 blockbuster mAbs whose patents will expire between 2025 and 2030. These expirations, affecting some of pharma's biggest players, will have a major impact on the market and their revenue streams.
ISPOR 2025
ISPOR
info@ispor.org https://www.ispor.org/conferences-education/event/2025/05/13/default-calendar/ispor-2025Montreal
15th World ADC London Summit 2025
Hanson Wade
adc@hansonwade.com https://worldadc-europe.com/London
